VANCOUVER, B.C., May 10, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases ("Novelion" or the "Company"), today reported financial results for the first quarter ended March 31, 2018 and provided an overview of business activities.
Recent Press Releases
Aegerion strengthens balance sheet and liquidity, positioning company for ongoing capital structure review
Novelion reports 2017 total net revenues of $138.4 million, in line with previously stated guidance
Plans underway to address capital structure and advance metreleptin development program